UBS Group AG Reduces Holdings in Establishment Labs Holdings Inc. $ESTA

UBS Group AG cut its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 51.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,389 shares of the company’s stock after selling 44,656 shares during the quarter. UBS Group AG owned 0.14% of Establishment Labs worth $3,016,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Geode Capital Management LLC boosted its holdings in Establishment Labs by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after acquiring an additional 299 shares during the period. Private Advisor Group LLC lifted its holdings in Establishment Labs by 14.1% in the 3rd quarter. Private Advisor Group LLC now owns 5,450 shares of the company’s stock worth $223,000 after buying an additional 675 shares during the period. Quarry LP purchased a new stake in Establishment Labs in the 3rd quarter worth approximately $34,000. First Light Asset Management LLC lifted its holdings in Establishment Labs by 0.3% in the 3rd quarter. First Light Asset Management LLC now owns 418,358 shares of the company’s stock worth $17,148,000 after buying an additional 1,201 shares during the period. Finally, Sei Investments Co. lifted its holdings in Establishment Labs by 2.8% in the 3rd quarter. Sei Investments Co. now owns 49,770 shares of the company’s stock worth $2,040,000 after buying an additional 1,342 shares during the period. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the transaction, the director owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. This represents a 10.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders sold 330,000 shares of company stock valued at $22,854,538. 9.99% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Needham & Company LLC increased their price objective on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a report on Wednesday, May 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. Stephens increased their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Finally, BTIG Research increased their price objective on Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $87.14.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA opened at $72.19 on Tuesday. Establishment Labs Holdings Inc. has a 52-week low of $33.35 and a 52-week high of $83.31. The firm has a market capitalization of $2.12 billion, a P/E ratio of -48.45 and a beta of 1.12. The stock has a 50 day moving average price of $64.76 and a 200-day moving average price of $68.24. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The firm had revenue of $59.88 million during the quarter, compared to the consensus estimate of $57.40 million. During the same period in the prior year, the company posted ($0.70) EPS. The firm’s revenue was up 44.7% on a year-over-year basis. As a group, equities research analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 EPS for the current fiscal year.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.